Given that human CRC was highly infiltrated with C5aR1+ TAMs, and that an increase in survival was observed in CRC patients with C5aR1- TAM tumors, we asserted that these malignancies could benefit from therapies targeting C5aR1. This evidence concerns the gene C5AR1 and colorectal carcinoma.